Deakin University
Browse

File(s) under permanent embargo

ASPREE-D: Aspirin for the prevention of depression in the elderly

Version 2 2024-06-05, 07:41
Version 1 2016-12-16, 14:31
journal contribution
posted on 2024-06-05, 07:41 authored by Michael BerkMichael Berk, RL Woods, MR Nelson, RC Shah, CM Reid, E Storey, SM Fitzgerald, JE Lockery, R Wolfe, Mohammadreza MohebbiMohammadreza Mohebbi, AM Murray, B Kirpach, R Grimm, JJ McNeil
ABSTRACTBackground:Not only is depression associated with increased inflammation but inflammation is a risk factor for the genesis of depression. Many of the environmental risk factors for depression are transduced through inflammatory signaling. Anti-inflammatory agents show promise for the management of depression in preclinical, epidemiological, and early clinical studies. This opens the door to the potential for anti-inflammatory agents to treat and prevent depression. There are no evidence-based pharmacotherapies for depression prevention.Method:ASPREE-D, aspirin in the prevention of depression in the elderly, is a sub study of ASPREE, which explores the potential of aspirin to prevent a range of inflammation related disorders in the elderly. With a sample size of 19,114, and a duration of 5 years, this placebo controlled study will be one of the largest randomized controlled trials in psychiatry and will provide definitive evidence on the ability of aspirin to prevent depression.Results:This paper presents the rationale for the study and presents a summary of the study design.Conclusions:ASPREE-D may not only define novel therapy but will provide mechanistic proof of concept of the role of inflammation in depression.

History

Journal

International Psychogeriatrics

Volume

28

Pagination

1741-1748

Location

England

ISSN

1041-6102

eISSN

1741-203X

Language

English

Publication classification

C1 Refereed article in a scholarly journal, C Journal article

Copyright notice

2016, International Psychogeriatric Association

Issue

10

Publisher

CAMBRIDGE UNIV PRESS